11,054 Shares in Sotera Health Company $SHC Purchased by Galvin Gaustad & Stein LLC

Galvin Gaustad & Stein LLC bought a new position in shares of Sotera Health Company (NASDAQ:SHC) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 11,054 shares of the company’s stock, valued at approximately $123,000.

Other institutional investors have also added to or reduced their stakes in the company. UMB Bank n.a. grew its position in Sotera Health by 112.8% during the second quarter. UMB Bank n.a. now owns 2,635 shares of the company’s stock worth $29,000 after buying an additional 1,397 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its position in Sotera Health by 3,690.1% during the first quarter. Caitong International Asset Management Co. Ltd now owns 2,691 shares of the company’s stock worth $31,000 after buying an additional 2,620 shares in the last quarter. Parallel Advisors LLC grew its position in Sotera Health by 124.0% during the second quarter. Parallel Advisors LLC now owns 3,340 shares of the company’s stock worth $37,000 after buying an additional 1,849 shares in the last quarter. Summit Securities Group LLC acquired a new stake in Sotera Health during the first quarter worth about $67,000. Finally, Farther Finance Advisors LLC grew its position in Sotera Health by 4,881.9% during the first quarter. Farther Finance Advisors LLC now owns 6,327 shares of the company’s stock worth $70,000 after buying an additional 6,200 shares in the last quarter. 91.03% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

SHC has been the topic of a number of recent research reports. Barclays lifted their target price on Sotera Health from $17.00 to $19.00 and gave the stock an “overweight” rating in a research report on Thursday, October 2nd. Weiss Ratings reissued a “sell (d)” rating on shares of Sotera Health in a research report on Wednesday. Finally, Wall Street Zen upgraded Sotera Health from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 16th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $17.20.

Insider Buying and Selling

In related news, insider Michael P. Rutz sold 126,611 shares of the stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $16.38, for a total transaction of $2,073,888.18. Following the sale, the insider directly owned 450,204 shares in the company, valued at $7,374,341.52. This represents a 21.95% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Gtcr Investment Xi Llc sold 8,000,000 shares of the stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $15.11, for a total value of $120,880,000.00. Following the sale, the director owned 41,215,301 shares in the company, valued at approximately $622,763,198.11. This trade represents a 16.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 20,126,611 shares of company stock worth $304,273,888 in the last three months. Insiders own 47.55% of the company’s stock.

Sotera Health Trading Down 2.7%

SHC stock opened at $15.35 on Friday. Sotera Health Company has a 1-year low of $9.53 and a 1-year high of $16.64. The firm has a market cap of $4.36 billion, a P/E ratio of 191.90 and a beta of 1.82. The business’s 50 day moving average is $15.50 and its 200-day moving average is $12.98. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 4.49.

Sotera Health (NASDAQ:SHC) last released its quarterly earnings data on Friday, August 8th. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.17 by $0.03. Sotera Health had a return on equity of 39.42% and a net margin of 2.14%.The company had revenue of $294.34 million for the quarter, compared to analyst estimates of $275.81 million. During the same period in the prior year, the company posted $0.19 EPS. The company’s revenue was up 6.4% compared to the same quarter last year. Sotera Health has set its FY 2025 guidance at 0.750-0.820 EPS. Equities analysts anticipate that Sotera Health Company will post 0.61 earnings per share for the current fiscal year.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.